Funding boost gets Sunho Biologics over the IPO filing line
The cash-burning biotech has applied to list on the Hong Kong Stock Exchange after only barely achieving the minimum market value Key Takeaways: With no product or licensing revenue, Sunho…
Laekna IPO hopes to hitch a ride on Novartis ties
The producer of drugs licensed from third parties is banking on ties to the Swiss drug maker, as one of its key products nears the regulatory finish line Key Takeaways:…
RELATED ARTICLES
-
InSilico seeks IPO boost to get AI drugs over the line
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
